DCT

1:25-cv-01246

Bayer Healthcare Pharma Inc v. Aurobindo Pharma Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:

  • Case Identification: 1:25-cv-01246, D. Del., 08/25/2026

  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Aurobindo Pharma U.S.A., Inc. is a Delaware corporation, and its foreign parent, Aurobindo Pharma Ltd., is subject to personal jurisdiction in the district through its control of the U.S. subsidiary and its history of litigating in the district.

  • Core Dispute: Plaintiff alleges that Defendant's proposed generic version of the drug KERENDIA® (finerenone), as described in its Abbreviated New Drug Application (ANDA), infringes two patents related to the preparation and composition of the finerenone active ingredient.

  • Technical Context: The technology concerns pharmaceutical chemistry, specifically methods for preparing and purifying finerenone, a non-steroidal mineralocorticoid receptor antagonist used for treating chronic kidney disease and heart failure.

  • Key Procedural History: U.S. Reissue Patent No. RE49,826 is a reissue of U.S. Patent No. 10,336,749, which may impact claim scope and potential intervening rights arguments. The litigation was triggered by Defendant's Paragraph IV certification notice asserting that its generic product would not infringe or that the patents are invalid.

Case Timeline

Date Event
2015-08-21 RE'826 Patent Priority Date
2018-04-24 '381 Patent Priority Date
2019-07-02 Original U.S. Patent No. 10,336,749 Issue Date
2021-07-09 FDA Approval of KERENDIA® (NDA No. 215341)
2024-02-06 RE'826 Patent Issue Date
2025-08-26 Aurobindo sends Paragraph IV Notice Letter
2025-08-28 Bayer receives Paragraph IV Notice Letter
2025-10-21 '381 Patent Issue Date
2026-08-25 First Amended Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. RE49,826 - "Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient," issued February 6, 2024.

The Invention Explained

  • Problem Addressed: The patent describes prior research-scale synthesis methods for finerenone as being unsuitable for industrial production due to factors like low yields, high dilution, excessive reagent use, and a dependency on multiple, costly chromatographic purification steps RE49,826 Patent, col. 1:49-62
  • The Patented Solution: The invention discloses a more efficient, scalable four-stage process that avoids intermediate chromatographic purifications RE49,826 Patent, col. 2:61-67 A key aspect is the use of preparative chiral HPLC to separate the desired (4S) enantiomer from its racemate, followed by a specific crystallization process to isolate the final compound as a defined stable crystal form, "polymorph I" RE49,826 Patent, col. 13:1-24
  • Technical Importance: The patented method provides a commercially viable pathway to manufacture a therapeutically important compound in a specific, highly pure, and stable crystalline form required for pharmaceutical formulation.

Key Claims at a Glance

  • The complaint alleges infringement of "one or more claims" of the RE'826 Patent Compl. ¶62 Independent claim 14 is a representative product-by-process claim.
  • Claim 14 Elements:
    • A compound of the formula (I) [finerenone] in crystalline form of polymorph I.
    • Wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 12,448,381 - "Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters," issued October 21, 2025.

The Invention Explained

  • Problem Addressed: The patent identifies chromatographic separation of enantiomers (the mirror-image forms of a chiral molecule) as being expensive, difficult to scale, and associated with high solvent consumption '381 Patent, col. 3:40-54 At the same time, conventional chemical separation via salt formation was not expected to work for finerenone due to its specific chemical properties (pKs value) '381 Patent, col. 3:55-62
  • The Patented Solution: The invention is based on the discovery that specific aromatically substituted tartaric acid derivatives, such as dibenzoyltartaric acid, can successfully form stable, isolable diastereomeric salts (or "molecular 1:1 aggregates") with finerenone '381 Patent, col. 8:25-32 This enables an efficient, scalable, non-chromatographic separation of the desired enantiomer. The patent also claims compositions of finerenone containing trace amounts of this resolving agent, which defines a specific purity profile resulting from this process '381 Patent, col. 29:3-10
  • Technical Importance: This process provides a more cost-effective and industrially scalable alternative to preparative chromatography for producing the single active enantiomer of finerenone.

Key Claims at a Glance

  • The complaint asserts infringement of "at least claim 1" of the '381 Patent Compl. ¶79
  • Claim 1 Elements:
    • A composition comprising finerenone (I).
    • And a dibenzoyltartaric acid of formula (III).
    • Wherein the composition has a dibenzoyltartaric acid content of >0.006% and less than or equal to 0.15% by weight of finerenone (I).
  • Claims 2-20 are dependent claims reciting further limitations, including specific impurity ranges and crystalline form Compl. ¶¶40-41 The complaint does not explicitly reserve the right to assert these.

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Aurobindo's proposed generic finerenone drug product, for which it seeks FDA approval under ANDA No. 220696 Compl. ¶1
  • Functionality and Market Context: The product is described as tablets containing 10 mg and 20 mg of finerenone Compl. ¶27 The complaint alleges that this product is a pharmaceutical composition that comprises not only finerenone but also dibenzoyltartaric acid within a specific, narrow concentration range Compl. ¶53 Compl. ¶80 This allegation directly implicates the claims of the '381 patent, suggesting the product possesses a chemical fingerprint tied to the patented purification method. The product is intended to be a generic substitute for Bayer's KERENDIA®, a treatment for conditions associated with chronic kidney disease and heart failure Compl. ¶1 Compl. ¶32

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

For U.S. Reissue Patent No. RE49,826, the complaint does not provide sufficient detail for analysis of infringement. The complaint makes a general allegation of infringement under 35 U.S.C. § 271(e)(2)(A) by the filing of the ANDA but does not plead specific facts as to how Aurobindo's product will meet the limitations of any claim, such as being the claimed "polymorph I" Compl. ¶60

U.S. Patent No. 12,448,381 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A composition comprising finerenone (I) The ANDA Product is alleged to be a pharmaceutical composition in tablet form that comprises finerenone of formula (I). ¶52; ¶80 col. 6:25-38
and a dibenzoyltartaric acid of formula (III) The ANDA Product is alleged to comprise dibenzoyltartaric acid of formula (III). ¶52; ¶80 col. 29:25-40
wherein the composition has a dibenzoyltartaric acid content of >0.006% and less than or equal to 0.15% by weight of finerenone (I). The ANDA Product is alleged to have a dibenzoyltartaric acid content that is greater than 0.006% and less than or equal to 0.15% by weight of finerenone. ¶53; ¶80 col. 58:1-3
  • Identified Points of Contention:
    • Scope & Evidentiary Questions (RE'826 Patent): A central issue will be whether Aurobindo's product meets the structural requirements of the asserted claims. For example, for claim 14, this raises the evidentiary question of whether the accused product is, in fact, the claimed "polymorph I" as defined by the patent's specified X-ray diffractogram peaks. The complaint is currently silent on this point.
    • Factual & Evidentiary Questions ('381 Patent): The infringement allegation for the '381 patent is factually specific. The dispute will likely center on an analytical-chemical question: does Aurobindo's finished drug product, as submitted in its ANDA, actually contain "dibenzoyltartaric acid" within the precisely claimed range of >0.006% to ≤0.15%? The case may turn on the results of laboratory testing of the accused product.

V. Key Claim Terms for Construction

  • The Term: "a dibenzoyltartaric acid content of >0.006% and less than or equal to 0.15% by weight of finerenone (I)" '381 Patent, claim 1
  • Context and Importance: This term defines a specific impurity profile for the finerenone composition. Practitioners may focus on this term because the infringement theory articulated in the complaint hinges on Aurobindo's product falling within this precise numerical range. The lower bound of ">0.006%" is particularly critical, as a product with an impurity level below this threshold may not literally infringe the claim.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue that the claim covers any finerenone product containing this specific impurity within the claimed range, potentially as an inherent marker of a manufacturing process that uses dibenzoyltartaric acid as a resolving agent. The patent describes a process that results in this impurity and then works to reduce it, suggesting its presence is tied to the patented method '381 Patent, col. 21:38-60
    • Evidence for a Narrower Interpretation: A party could argue the claim is a strict definition of a composition, not a process marker, and must be read as a precise numerical limitation. The patent discloses extensive efforts to purify the final product and reduce the level of this very impurity to "below 0.15%, preferably below 0.1% and in particular to below 0.05%" '381 Patent, col. 21:49-56 This emphasis on high purity could support an argument that the claim defines a specific, narrow state of the composition that must be strictly met.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Aurobindo will induce and contribute to infringement by healthcare professionals and patients who use the accused product in accordance with its label Compl. ¶71 Compl. ¶89
  • Willful Infringement: The complaint alleges that Aurobindo acted with full knowledge of the patents-in-suit and without a reasonable basis for believing its product would not infringe, pointing to Aurobindo's submission of a Paragraph IV certification as evidence of pre-suit knowledge Compl. ¶64 Compl. ¶83

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of structural identity: does Aurobindo's generic product consist of the specific "polymorph I" of finerenone as defined by the structural characteristics recited in the RE'826 Patent, a factual point not yet detailed in the pleadings?
  • The case for the '381 patent appears to hinge on a question of analytical chemistry: does Aurobindo's final drug product contain trace amounts of dibenzoyltartaric acid that fall squarely within the narrow quantitative range defined by claim 1, potentially serving as a fingerprint of the patented purification process?